Medical devices manufacturer Helius Medical Technologies has raised $500 million through a private placement in public equity (PIPE) to create a Solana treasury, the company announced on Monday, part of a growing list of Nasdaq-traded companies shifting their focus to accumulate SOL. Venture capital firms Pantera Capital and Summer Capital led the offering, which also included Big Brain Holdings, Avenir, FalconX, Arrington Capital, Animoca Brands, and HashKey Capital, among others. The offering is expecte ...

The Dominican Republic is emerging as a growing force in the medical device manufacturing sector. This month's cover feature examines the rising appeal of the nation as it emerges as a nearshoring hub for global medtech firms seeking supply chain resilience and cost efficiency in the post-pandemic landscape. Also in this issue, we look at the growing capsule endoscopy market and the prospects and hurdles surrounding its potential to supersede the traditional endoscopy market in the near-term future. Mean ...

Core Insights - Nordson Corporation (NDSN) has divested its design and development contract manufacturing business units to Quasar Medical, with financial terms undisclosed [1][8] - Following the announcement, Nordson's shares fell by 1.1%, closing at $222.70 [1] Business Operations - Nordson Medical's contract manufacturing businesses, located in Galway, Ireland, and Tecate, Mexico, provide comprehensive solutions for complex interventional devices in the medical industry [2] - The Galway facility will now serve as Quasar Medical's innovation center for advanced medical device manufacturing processes, while the Tecate facility will function as a manufacturing hub for packaging, coating, molding, and automated processes [3] Strategic Alignment - This divestment aligns with Nordson's business transformation strategy aimed at unlocking shareholder value by focusing on core operations and optimizing its Medical and Fluid Solutions portfolio [4] - The divestiture allows Nordson to strengthen its medical component offerings, which include cannulas, catheters, medical balloons, and fluid management solutions [4] Market Performance - Nordson has a market capitalization of $12.5 billion and currently holds a Zacks Rank 2 (Buy) [5] - The company is experiencing strong momentum in its Advanced Technology Solutions segment, driven by customer demand in nonwovens, packaging, consumer non-durable, and optical sensors product lines [5] - Over the past month, Nordson's shares have increased by 4.8%, outperforming the industry growth of 2.4% [6] - The Zacks Consensus Estimate for Nordson's fiscal 2025 earnings is projected at $10.07 per share, reflecting a 0.4% increase from the previous estimate [6]

This milestone enhances Quasar's global CDMO platform, broadening end-to-end capabilities and providing increased value for medical device OEMs and innovators.GALWAY, Ireland, Sept. 2, 2025 /PRNewswire/ -- Quasar Medical, a global leader in manufacturing interventional and minimally invasive medical devices, today announced the completion of its acquisition of Nordson Corporation's (Nasdaq: NDSN) design & development contract manufacturing businesses in Galway, Ireland, and Tecate, Mexico.Quasar's evolution ...

BROOKLYN PARK, Minn., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Cirtec Medical, a leading strategic outsourcing partner for complex minimally invasive, active implantable devices and precision components, is pleased to announce the appointment of Shar Matin as Chief Executive Officer, effective September 2, 2025. About Cirtec Medical Cirtec Medical is a global leader in design, development, and manufacturing of complex Class II and III medical devices, specializing in active implant systems, interventional devices, ...

Summary of UFP Technologies Conference Call Company Overview - UFP Technologies (Ticker: UFPT) is based in Newburyport, Massachusetts with a market cap close to $2 billion and revenue of approximately $600 million, of which about $550 million is from medical revenue [6][34] - The company operates 22 locations globally with around 4,000 employees and has six development labs that are crucial for its contract development manufacturing organization (CDMO) model [7][34] Core Business and Innovations - UFP Technologies specializes in developing innovative medical devices that improve patient outcomes, working with 26 of the top 30 medical device companies globally [6][8] - The company focuses on high-margin product development, engaging clients early in the development process to create custom manufacturing processes [9][34] - Key technologies include negative pressure wound therapy, robotic surgical drapes, and infection prevention devices [10][15][18] Market Opportunity - The medtech market is valued at $500 billion and is growing at 6.3%, while the outsourcing market is close to $100 billion and growing at 10-11% [20][29] - UFP Technologies targets segments with high risk of failure and low average selling prices, particularly in single-use, plastic-based products [21][36] - The company has identified over 20 defined segments in the medical space, servicing eight with revenues of $15 million or more [22][36] Growth Strategy - UFP Technologies employs a two-pronged growth strategy focusing on organic growth in faster-growing segments and strategic acquisitions [25][27] - The management team has a history of successful acquisitions, completing nine deals in the medtech space since 2021 [27][34] - Financial targets include revenue growth of 12-18% and gross margins of 28-31% [34][35] Competitive Landscape - The market is highly fragmented with approximately 900 private equity-backed CDMOs, making it challenging for new entrants due to regulatory barriers [38] - UFP Technologies has established strong relationships with major clients like Intuitive Surgical and Stryker, which are critical for its growth [39][40] Financial Performance - Medical revenue has grown from $132 million to $540 million, representing a compound annual growth rate (CAGR) of approximately 40% [28][34] - The company has experienced some headwinds related to onboarding new employees but remains confident in meeting its financial targets [51][53] Key Differentiators - UFP Technologies boasts a team of over 100 engineers who provide technical value and foster strong supplier relationships, giving the company a competitive edge [32][34] - The company emphasizes customer-centric M&A, focusing on adding value to clients and enhancing capabilities [28][36] Conclusion - UFP Technologies is positioned in a growing market with significant opportunities for outsourcing and innovation, backed by a proven management team and a strong growth strategy [36][37]

Core Viewpoint - Integer Holdings Corporation is actively participating in the 2025 Wells Fargo Healthcare Conference, indicating its commitment to engaging with investors and stakeholders in the healthcare sector [1]. Company Overview - Integer Holdings Corporation (NYSE: ITGR) is a leading medical device contract development and manufacturing organization (CDMO) globally, focusing on cardiac rhythm management, neuromodulation, and cardio and vascular markets [3]. - The company serves as a strategic partner for medical device companies and OEMs, aiming to enhance patient lives through innovative and high-quality products [3]. - Integer's notable brands include Greatbatch Medical and Lake Region Medical, reflecting its strong market presence [3]. Event Participation - The executive leadership team of Integer will participate in a fireside chat during the conference on September 4 at 3:00 p.m. ET, showcasing the company's proactive approach to investor relations [1]. - A live webcast of the presentation will be available on the Investor Relations section of the Integer website, ensuring accessibility for interested parties [2].

Core Insights - BD (Becton, Dickinson and Company) plans to invest over $35 million to expand prefilled flush syringe manufacturing at its Columbus, Nebraska facility, creating approximately 50 new jobs to enhance the resiliency of the U.S. healthcare system [1][2][7] Investment and Production Capacity - The investment will support new production lines for BD® PosiFlush™ Prefilled Flush Syringes, enabling the company to produce hundreds of millions of additional units annually to meet the growing demand from U.S. hospitals and health systems [3][6] - Over the past three years, BD has invested more than $80 million to expand PosiFlush™ capacity, increasing U.S. production by over 750 million units, including a 10% increase this year [6] Product Importance and Quality Assurance - PosiFlush™ Prefilled Flush Syringes are critical for catheter care and medication delivery, used in nearly every hospital in the U.S. to prevent catheter-related complications [4] - The syringes are manufactured using a fully automated, hands-free process, ensuring that the first person to touch the syringe is the clinician, which helps reduce contamination risks [5] Broader Commitment to U.S. Healthcare - This announcement is part of BD's broader commitment to strengthen U.S. healthcare infrastructure, with plans to invest $2.5 billion in U.S. manufacturing capacity over the next five years [7] - BD operates over 30 manufacturing and distribution facilities across 17 states and Puerto Rico, employing more than 10,000 people, forming a critical backbone of the U.S. medical device supply chain [8]

Core Insights - Trout Capital Advisors served as the exclusive financial advisor to Universal Plastics & Engineering Company, Inc. in its sale to UFP Technologies, Inc. [1] - UNIPEC specializes in precision thermoformed and heat-sealed polymer components for Class III implantable medical devices, making it a strategic fit for UFP Technologies' medical-focused portfolio [2] - The transaction is viewed as a strong strategic outcome for UNIPEC, emphasizing the importance of legacy and future opportunities for employees [2] Company Overview - Trout Capital Advisors is a boutique investment banking firm focused on lower-middle market businesses, particularly founder- and family-owned companies [4] - UNIPEC has been a family-owned business since 1957, highlighting its long-standing legacy in the industry [2] - UFP Technologies, Inc. is a designer and manufacturer of custom-engineered components for the medical market, indicating its commitment to innovation in healthcare [1][2] Transaction Details - The sale of UNIPEC to UFP Technologies represents a significant event in the company's history, facilitating its next chapter [2] - The transaction underscores Trout Capital Advisors' expertise in advising privately held businesses in advanced manufacturing and engineered products sectors [2]

Core Insights - UFP Technologies, Inc. has announced the acquisitions of Universal Plastics & Engineering Company, Inc. (UNIPEC) and Techno Plastics Industries, Inc. (TPI) to enhance its capabilities in the medical device market [1][5] - The acquisitions are aimed at expanding UFP's offerings in tight tolerance film components and thermoplastic molding, which are critical for medical devices [1][5] Company Overview - UFP Technologies is a designer and custom manufacturer of solutions for medical devices, sterile packaging, and other engineered products, serving top medical device manufacturers globally [5] - The company specializes in single-use and single-patient devices used in various medical applications, including minimally invasive surgery and infection prevention [5] Acquisition Details - UNIPEC, based in Rockville, Maryland, specializes in precision thermoformed and heat-sealed polymer components for Class III implantable medical devices, contributing to UFP's thin film platform [2][3] - TPI, located in Anasco, Puerto Rico, is a manufacturer of precision thermoplastic injection-molded components, enhancing UFP's thermoplastic molding capabilities [3][4] - UNIPEC has approximately $5 million in revenue and $2 million in EBITDA, while TPI has around $10 million in revenue and $1 million in EBITDA [7] Strategic Fit - The acquisitions are seen as strategic fits that will strengthen UFP's partnerships with leading medical device OEMs by adding unique technologies and expertise [5] - The integration of UNIPEC and TPI is expected to bolster UFP's production scale and capabilities in high-growth sectors of the medical device market [5][6]